{"id":38560,"date":"2025-09-22T10:07:13","date_gmt":"2025-09-22T08:07:13","guid":{"rendered":"https:\/\/der-arzneimittelbrief.com\/?p=38560"},"modified":"2025-09-18T12:16:32","modified_gmt":"2025-09-18T10:16:32","slug":"sglt2-inhibitoren-ketoazidosen-gibt-es-auch-bei-patienten-ohne-diabetes-mellitus-cme","status":"publish","type":"post","link":"https:\/\/der-arzneimittelbrief.com\/artikel\/2025\/sglt2-inhibitoren-ketoazidosen-gibt-es-auch-bei-patienten-ohne-diabetes-mellitus-cme","title":{"rendered":"SGLT2-Inhibitoren \u2013 Ketoazidosen gibt es auch bei Patienten ohne Diabetes mellitus [CME]"},"content":{"rendered":"<p>SGLT2-Inhibitoren bei Diabetes mellitus: Dapagliflozin und Empagliflozin werden bereits seit &gt;\u00a015\u00a0Jahren zur Behandlung von Patienten mit Typ2 Diabetes mellitus (DMT2) eingesetzt (vgl.\u00a0). Gliflozine sind reversible, selektive kompetitive Inhibitoren des Sodium-Glucose-Cotransporters-2 (SGLT2). SGLT2 wird v.a. in der Niere stark exprimiert, und er ist der ma\u00dfgebliche Transporter f\u00fcr die R\u00fcckresorption von Glukose aus dem glomerul\u00e4ren Filtrat. SGLT2-Inhibitoren [&hellip;]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>SGLT2-Inhibitoren bei Diabetes mellitus: Dapagliflozin und Empagliflozin werden bereits seit &gt;\u00a015\u00a0Jahren zur Behandlung von Patienten mit Typ2 Diabetes mellitus (DMT2) eingesetzt (vgl.\u00a0). Gliflozine sind reversible, selektive kompetitive Inhibitoren des Sodium-Glucose-Cotransporters-2 (SGLT2). SGLT2 wird v.a. in der Niere stark exprimiert, und er ist der ma\u00dfgebliche Transporter f\u00fcr die R\u00fcckresorption von Glukose aus dem glomerul\u00e4ren Filtrat. SGLT2-Inhibitoren [&hellip;]<\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[1554,1556,155,1555,1558,1559,1557,256,1552,1550,1551],"class_list":["post-38560","post","type-post","status-publish","format-standard","hentry","category-allgemein","tag-azidose","tag-dapagliflozin","tag-diabetes-mellitus-typ-2","tag-empagliflozin","tag-gliflozine","tag-ketoazidose","tag-natrium-glukose-cotransporter-2","tag-nebenwirkungen","tag-sglt2","tag-sglt2-hemmer","tag-sglt2-inhibitoren"],"_links":{"self":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/38560","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/comments?post=38560"}],"version-history":[{"count":0,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/38560\/revisions"}],"wp:attachment":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/media?parent=38560"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/categories?post=38560"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/tags?post=38560"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}